Broken RECORD: New Themes, Same Old Story for Avandia
This article was originally published in RPM Report
Executive Summary
Rosa DeLauro came to an Institute of Medicine meeting on regulatory science to praise FDA’s new leadership and to take credit for increasing its resources. But she also trashed the agency’s handling of Avandia. It isn’t clear that science has anything to do with that debate, but resolving it looks like a critical test for the agency and its new leadership this summer.